2024 End of Year Report

2024 ASH Research and Public Health Funding Advocacy Highlights

During 2024, ASH continued to be highly visible in our advocacy for federal support of biomedical research and public health funding, including funding for the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Health Resources and Services Administration (HRSA). ASH also encouraged federal support for the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP), which is allocated via the annual Defense Appropriations bill, and research at the U.S. Veteran’s Administration (VA). ASH and other members of the biomedical research and public health communities have strongly urged Congress to provide increased funding for these Agencies. The following overview provides information on advocacy highlights in research and public health funding.

2024 Year-end Physician Practice Advocacy Highlights

In 2024, ASH commented on legislation and federal rules impacting Medicare physician payment and related issues to ensure that hematologists are appropriately reimbursed for the care they provide to patients with hematologic diseases and disorders.

2024 ASH Advocacy Efforts Related to Sickle Cell Disease

In 2024, ASH was actively advocating for issues impacting hematology research and practice, including research and public health funding, access to quality care for patients, physician payment and coverage for hematologists, and policy issues related to sickle cell disease (SCD).

ASH continues to guide and lead sickle cell advocacy before the US Congress and federal agencies, with a focus on urging access to high-quality, comprehensive care for individuals with sickle cell disease (SCD). The following overview highlights ASH’s sickle cell-focused advocacy in 2024.

2024 ASH Advocacy Efforts to Ensure Patient Access to Care

During 2024, ASH continued to be highly visible in our advocacy on issues that ensure patient access to affordable health care, including maternal health and hematology, drug shortage issues, and access to safe and effective hematologic therapies. The following is a summary of advocacy efforts that ASH pursued with the Federal Administration and the U.S. Congress throughout 2024.

Additional Information

For additional information about ASH efforts to ensure access in hematology, please see the 2024 ASH Advocacy Efforts related to Physician Practice, and Sickle Disease.